PDCD1 and sarcoma: We then performed a comprehensive immunological phenotyping of splenocytes and intratumor cells (Supplementary information, Fig. S2a, b) after 4 administrations of anti-PD-1 mAb in sensitive (MCA205WT sarcoma), eventually resistant (MCA205OVA sarcoma) and innately resistant (AT3 breast cancer) tumor models.